Cargando…
Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study
Patient's quality of life should be included in clinical decision making regarding the administration of adjuvant chemotherapy (ACT) in stage II/III colon cancer. Therefore, quality of life, summarized as health utility (HU), was evaluated for patients treated with and without ACT. Furthermore,...
Autores principales: | Jongeneel, Gabrielle, Greuter, Marjolein J. E., van Erning, Felice N., Twisk, Jos W. R., Koopman, Miriam, Punt, Cornelis J. A., Vink, Geraldine R., Coupé, Veerle M. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048818/ https://www.ncbi.nlm.nih.gov/pubmed/33460468 http://dx.doi.org/10.1002/ijc.33472 |
Ejemplares similares
-
Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data
por: Jongeneel, Gabrielle, et al.
Publicado: (2019) -
Model-based effectiveness and cost-effectiveness of risk-based
selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer
patients
por: Jongeneel, Gabrielle, et al.
Publicado: (2021) -
Model-based evaluation of the cost effectiveness of 3 versus 6 months’ adjuvant chemotherapy in high-risk stage II colon cancer patients
por: Jongeneel, Gabrielle, et al.
Publicado: (2020) -
Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)
por: Jongeneel, Gabrielle, et al.
Publicado: (2020) -
Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data
por: Hamers, Patricia A. H., et al.
Publicado: (2020)